ANCILLARY STUDY TO THE HALT-C ANTI-VIRAL LONG-TERM TREATMENT AGAINST CIRRHOSI

HALT-C 抗病毒长期治疗肝硬化的辅助研究

• 批准号: 8166566
• 负责人: Mitchell L Shiffman
• 金额: $ 0.13万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166566
• 关键词: Ancillary Study; Carcinoma; Chronic; Clinical; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Fibrosis; Frequencies; Funding; Grant; Institution; Outcome; Patients; Research; Research Personnel; Resources; Ribavirin; Source; Staging; United States National Institutes of Health; Viral; cohort; experience; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to establish a cohort of chronic hep-C patients with Ishak stage 3-6 fibrosis who experienced a sustained virologic response SVR after peginterferon and ribavirin combination therapy and access the frequency of clinical outcomes and heptocellular carcinoma and factors associated with these outcomes.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是建立一个队列的慢性丙型肝炎患者与Ishak 3-6期纤维化谁经历了持续的病毒学应答SVR聚乙二醇干扰素和利巴韦林联合治疗后，并访问的频率临床结果和肝细胞癌和与这些结果相关的因素。